Paliperidone Eg (Paliperidone)

Paliperidone Eg is indicated for the treatment of schizophrenia and related psychotic disorders, acting on dopamine pathways to stabilize mood and perception.

• Schizophrenia: Reduces frequency of psychotic episodes and helps maintain symptom control.
• Schizoaffective disorder: Alleviates both mood and psychotic components.
• Bipolar I disorder (maintenance): Assists in preventing recurrence of manic or depressive episodes.

• Paliperidone is the primary active metabolite of risperidone and works by antagonising dopamine D2 and serotonin 5‑HT2A receptors. This receptor blockade reduces dopaminergic transmission in mesolimbic pathways, which helps to mitigate psychotic symptoms while also modulating serotonergic activity that influences mood and cognition.

Paliperidone may cause a range of adverse reactions, from mild to serious. Monitoring and reporting of side effects are essential for safe use.

Common Side Effects

• Headache: mild to moderate intensity.
• Insomnia: difficulty falling or staying asleep.
• Restlessness (akathisia): feeling of inner restlessness.
• Weight gain: increase in body weight over time.
• Dry mouth: reduced salivation.
• Dizziness: light‑headed sensation, especially when standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: persistent involuntary movements, often of the face.
• Seizures: occurrence of convulsive episodes.
• Orthostatic hypotension: significant drop in blood pressure upon standing.
• Hyperglycaemia: elevated blood glucose levels, may worsen diabetes.
• Cardiac arrhythmias: irregular heart rhythm, including QT prolongation.

When prescribing Paliperidone Eg, clinicians should consider several safety aspects to minimise risks.

• Cardiovascular assessment: evaluate for history of heart disease or arrhythmias.
• Metabolic monitoring: regularly check blood glucose and lipid profiles.
• Extrapyramidal symptoms: watch for signs of movement disorders.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks.
• Elderly patients: start with lower doses and monitor closely for sedation and falls.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Paliperidone may interact with other medications, altering its efficacy or safety profile. Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): increase paliperidone levels, raising toxicity risk.

• CNS depressants (e.g., benzodiazepines): additive sedation and respiratory depression.
• QT‑prolonging drugs (e.g., quinidine): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance blood‑pressure‑lowering effects.
• Antidiabetic agents: potential impact on glucose control.
• Anticholinergic drugs: may worsen dry mouth and constipation.
• NSAIDs: increased risk of gastrointestinal bleeding.
• Herbal supplements (e.g., St. John’s wort): possible alteration of drug metabolism.